Heron Therapeutics, Inc. (NASDAQ:HRTX) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.
Several other research analysts have also recently issued reports on HRTX. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Friday. Jefferies Group LLC reissued a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday. Noble Financial reissued a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, August 10th. Cowen and Company set a $40.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, ValuEngine raised Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating and eleven have assigned a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $31.00.
Shares of Heron Therapeutics (HRTX) traded up 0.33% during midday trading on Friday, hitting $15.30. 205,594 shares of the company’s stock traded hands. The company has a 50 day moving average of $15.50 and a 200 day moving average of $14.65. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $21.24.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. On average, equities analysts anticipate that Heron Therapeutics will post ($3.50) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.com-unik.info/2017/08/18/bidaskclub-lowers-heron-therapeutics-inc-hrtx-to-sell.html.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN boosted its position in shares of Heron Therapeutics by 78.8% in the first quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 17,442 shares in the last quarter. FMR LLC boosted its position in shares of Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock valued at $120,464,000 after buying an additional 2,158,041 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Heron Therapeutics during the first quarter valued at $2,002,000. Mesirow Financial Investment Management Equity Management purchased a new position in shares of Heron Therapeutics during the first quarter valued at $435,000. Finally, Tang Capital Management LLC boosted its position in shares of Heron Therapeutics by 39.7% in the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock valued at $129,824,000 after buying an additional 2,457,716 shares in the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
What are top analysts saying about Heron Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics Inc. and related companies.